tbuckley/cabot-search huggingface dataset:
Abstract 019: Diabetic Endothelial Progenitor Cells in Combination with an RGDS Presenting Peptide Amphiphile Enhance Recovery from Critical Limb Ischemia in Diabetic Mice
Authors: Erin E Vaughan, Eduard Sleep, Sol Misener, Aiko Ito Klinger, Veronica Ramirez, Tatiana V Abramova, Alexander R Mackie, Suresh Kumar Verma, Prasanna Krishnamurthy, Samuel I Stupp, Raj Kishore
Journal: Circulation Research (2013)

Approximately two million people suffer from critical limb ischemia (CLI) with the prevalence of the disease expected to rise. Thus, there is a crucial need to develop new therapies to enhance angiogenesis and minimize the impact of the blocked vessel(s). Cell therapy using endothelial progenitor cells (EPCs) has shown some promise, however, the cells may not remain at the site of injury long enough to significantly impact the course of the disease. Further, the use of autologous cells may be problematic as the underlying disease, such as diabetes, which resulted in CLI also appears to negatively impact the function of EPCs. Thus, we propose to use a biomaterial in combination with the EPCs to enhance both the retention of cells at the site of injury and also enhance the function of the cells. A self-assembling peptide amphiphile (PA) was developed with an attached functional group consisting of the cell-attachment sequence of peptides identified in fibronectin: RGDS. We hypothesize that EPCs combined with RGDS PA will improve the angiogenic response in CLI. Indeed, in vitro we found that EPCs from diabetic mice (db/db) exhibited increased survival on an RGDS PA in comparison to a scrambled sequence (DGRS) PA as measured by calcein-AM and ethidium homodimer-1 staining. To test if this enhanced survival would improve critical limb ischemia in diabetic mice, uni-lateral ischemia was induced by ligation of the femoral artery. Three days post surgery ischemia was confirmed by laser Doppler and the following treatments were injected into the ischemic limb of the diabetic mice: (1) PBS (2) scrambled PA (3) RGDS (4) scrambled PA +100,000 diabetic EPCs (5) RGDS PA + 100,000 diabetic EPCs. At four weeks post-injection, blood flow (as measured by laser Doppler) was increased in the group receiving RGDS PA when compared to the other groups (n&gt;6). Further, necrosis was decreased in the RGDS PA group and muscle regeneration, as measured by the number of central nuclei, was increased in the RGDS PA group. Taken together, these results suggest that RGDS PA in combination with db/db EPCs enhances recovery from CLI in diabetic mice.
ADIPOSE DERIVED STROMAL CELLS FOR REFRACTORY ANGINA: RESULTS FROM MYSTROMALCELL TRIAL
Authors: Abbas Ali Qayyum, Anders Mathiasen, Naja Mygind, Tobias Kuhl, Erik Joergensen, Steffen Helqvist, Jens Jørgen Elberg, Klaus Kofoed, Niels Vejlstrup, Anne Fischer-Nielsen, Mandana Haack-Sørensen, Annette Ekblond, Jens Kastrup
Journal: Journal of the American College of Cardiology (2017)
A phase II, randomized multi-center study of MDX-010 alone or in combination with dacarbazine (DTIC) in stage IV metastatic malignant melanoma
Authors: E. M. Hersh, J. Weber, J. Powderly, M. Yellin, K. Kahn, A. Pavlick, W. Samlowski, G. Nichol, S. O'Day
Journal: Journal of Clinical Oncology (2004)

7511 Background: MDX-010 is a human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 and augments immune responses. In stage IV melanoma patients MDX-010 given with a gp100 vaccine demonstrated responses that correlated with autoimmune toxicity (Autoimmune Breakthrough Events; ABEs). The current study determined the safety and activity of MDX-010 alone or with dacarbazine in Stage IV melanoma. Methods: 76 patients were enrolled and 72 received drug. Patients were randomized to receive MDX-010, 3 mg/kg monthly × 4 (arm A; n=37) or MDX-010 in combination with dacarbazine 250 mg/m2 for 5 days monthly × 4 (arm B; n=35). Responses were determined after 4 treatments. Results: The study arms were well balanced. ABEs were noted as follows. There were five Grade III ABEs in arm A; colitis (n=2), uveitis (n=2) and rash (n=1). There were six Grade III/IV ABEs in arm B; Grade III diarrhea/colitis (n=2), Grade III rash (n=2), Grade III increased ALT (n=1), and Grade IV hypersensitivity reaction (n=1). All ABEs but 1 resolved with treatment. One arm B patient had colitis complicated by C. difficile requiring colectomy. Two deaths were possibly attributed to MDX-010. Restaging data is currently available on 32 and 29 patients in arm A and B, respectively. Two PRs occurred in arm A and 1CR and 4PRs occurred in arm B. Four patients in arm A and 5 patients in arm B had SD (30–224+ days). Conclusions: MDX-010 alone or with dacarbazine can break tolerance and induce organ specific autoimmunity. This study suggests that combination therapy with dacarbazine may have greater clinical activity than monotherapy in patients with Stage IV melanoma. Future clinical trials of MDX-010 in combination with melanoma vaccines and chemotherapy are being planned. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Medarex, Inc. Medarex, Inc. Medarex, Inc. Medarex
HEART FAILURE PHENOTYPING BY LATENT CLASS ANALYSIS IDENTIFIES SUBPOPULATIONS AT HIGH RISK OF MORTALITY AND READMISSIONS: INSIGHTS FROM A REAL WORLD DATABASE
Authors: Cesare Russo, Xiao Shao, Zhenchao Guo, Chelsea Jin, Leah Burns, Alice Goshorn, Sanjay Doddamani
Journal: Journal of the American College of Cardiology (2017)
Phase II study of CC-5013 in patients (pts) with renal cell cancer (RCC)
Authors: P. Chapa, A. Rawat, R. J. Amato
Journal: Journal of Clinical Oncology (2004)

4761 Background: Immunomodulatory drugs are a series of compounds that have originated via the deliberate structural modification of thalidomide. CC-5013 is a derivative with enhanced immunological and anti-angiogenic properties without the toxicity associated with the parent compound. Objectives were to determine response, rate time to progression, one-year survival, and toxicity in patients with stage IV RCC. Methods: Eligibility included measurable disease, normal organ/marrow function, Zubrod Performance Stauts ≤ 2, life expectancy ≥ 3 months, ≤ 1 prior therapy, and no active CNS disease. CC-5013 was administered orally at a dose of 25 mg per day for 21 days with 7 days rest (28-day cycle), with dose reductions for toxicity. Re-evaluation will be done every three cycles. Results: Twenty-two patients have enrolled into the first stage. Patient characteristics; 17 male, 5 female, age ranges 44 - 73 (median 62) years were included; 22 had histologic confirmed renal cell cancer. 12 patients had received prior therapy. Previous cancer treatment was .. no prior treatment (N=10), immunotherapy (N=12), radiotherapy (N=5), chemotherapy (N=0).All patients had metastatic disease. Zubrod Performance Stauts 0 was (N=22). Sites of disease included lung, nodal, bone, and liver. Median number of sites of disease was 1 (range 1 to 3). 12 patients completed at least one cycle of therapy, 10 patients are presently receiving their first cycle of therapy. Conclusions: To date, no grade 3 or 4 toxicities have been reported. Additional results will be updated at the meeting. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Celgene Corporation
MULTICENTER EVALUATION OF THE ACURATE NEO TRANSFEMORAL TRANSCATHETER HEART VALVE – CLINICAL RESULTS AND PROPENSITY MATCHED COMPARISON WITH SAPIEN 3
Authors: Oliver Husser, Won-Keun Kim, Costanza Pellegrini, Andreas Holzamer, Thomas Walther, Patrick N. Mayr, Michael Joner, Albert M. Kasel, Jonathan Michel, Tobias Andreas Rheude, Adnan Kastrati, Heribert Schunkert, Christof Burgdorf, Michael Hilker, Helge Möllmann, Christian Hengstenberg
Journal: Journal of the American College of Cardiology (2017)
Vinorelbine-based salvage therapy for patients with aggressive leukemias and non-Hodgkin’s lymphomas
Authors: S. Morar, J. Larson, S. Qazi, F. Uckun
Journal: Journal of Clinical Oncology (2006)

17563 Background: We treated 26 patients with aggressive lymphohematopoietic malignancies, including 3 chronic myeloid leukemia (CML) patients in blast crisis, 2 chronic lymphocytic leukemia (CLL) patients with rapidly progressive leukemia, 10 acute lymphoblastic leukemia (ALL) patients in therapy refractory relapse, and 11 non-Hodgkin’s lymhoma (NHL) patients (9 in relapse with progressive lymphoma) with vinorelbine-based outpatient salvage chemotherapy. Methods: Patients received vinorelbine-based salvage therapy regimens NND-I (Vinorelbine [Navelbine] 25 mg/m 2 d1,d8, Mitoxantrone [Novantrone]10 mg/m 2 d1, Dexamethasone [Decadron] 20 mg BID d1 through 7, or NND-II (Vinorelbine 25 mg/m 2 d1, Mitoxantrone 10 mg/m 2 d1, Dexamethasone 20 mg BID d1 through 7, Fludarabine 25 mg/m 2 d1,d2,d3). Rituximab (Rituxan, 375 mg/m 2 d1,8,15,29) was used in combination with chemotherapy in patients with CD20 antigen positive malignancies. Treatment responses were evaluated by peripheral blood and bone marrow examinations in patients with leukemia and CT/MRI-PET fusion imaging in patients with non-Hodgkin’s lymphoma using standard response criteria. Results: All patients completed their salvage therapy as an outpatient without infectious disease complications or hospitalizations. Of the 26 patients, 20 (77%) had objective responses, including 14 complete remissions (CR). All 3 CML patients and both CLL patients achieved a CR. Of the 10 ALL patients, 5 achieved a CR and one achieved a partial remission (PR). Of the 11 NHL patients, 4 achieved a CR and 5 achieved a PR. Conclusions: Taken together, these findings demonstrate that patients with high risk/poor prognosis leukemias and non-Hodgkin’s lymphomas can achieve meaningful objective responses in an outpatient setting using vinorelbine-based salvage regimens. No significant financial relationships to disclose.
THE HIDDEN BURDEN OF EHR-IDENTIFIED FAMILIAL HYPERCHOLESTEROLEMIA: MORTALITY AND CLINICAL OUTCOMES
Authors: Prashant Patel, Amy Kolinovsky, Jeffrey Ruhl, Sarath Krishnamurthy, Dominik Beer, Lester Kirchner, Raghu Metpally, David Carey, Vishal Mehra
Journal: Journal of the American College of Cardiology (2017)
RIGHT VENTRICULAR REMODELLING IN HYPOPLASTIC LEFT HEART SYNDROME: IMPACT OF THE NORWOOD AND HYBRID PROCEDURES
Authors: Kandice Mah, Jesus Serrano Lomelin, Luke Eckersley, Lily Lin, Timothy Colen, Edythe Tham, Harald Becher, Luc Mertens, Nee Scze Khoo
Journal: Journal of the American College of Cardiology (2017)
UNINTERRUPTED NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS VERSUS WARFARIN IN PATIENTS UNDERGOING CARDIAC IMPLANTABLE ELECTRONIC DEVICE IMPLANTATION: A META-ANALYSIS
Authors: Mohit Turagam, Venkat Vuddanda, Poonam Velagapudi, Jayasree Pillarisetti, Mohammad-Ali Jazayeri, Madhav Lavu, Valay Parikh, Donita Atkins, Sudharani Bommana, Kul Aggarwal, Luigi Di Biase, Andrea Natale, Madhu Reddy, Dhanunjaya Lakkireddy
Journal: Journal of the American College of Cardiology (2017)
The Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) Regulates the Function and Migration of Leukemic Blasts through CD63/PI3K/AKT/P21 Axis
Authors: Dorian Forte, Valentina Salvestrini, Lucia Catani, Roberto M Lemoli, Michele Cavo, Antonio Curti
Journal: Blood (2015)
VENTRICULAR TACHYCARDIA EARLY AFTER IMPLANTATION OF A VENTRICULAR ASSIST DEVICE IS ASSOCIATED WITH INCREASED LONG TERM MORTALITY: A THIRTEEN YEAR INSTITUTIONAL EXPERIENCE
Authors: Brian D. Greet, Deep Pujara, David Burkland, Mark Pollet, Deepthi Sudhakar, Francia Rojas, Briana Costello, Alexander Postalian, Zachary Hale, Ben Jenny, Carol Lai, Kenneth Igbalode, Divesh Wadhera, Masahiro Ono, Jeffrey Morgan, Leo Simpson, Andrew Civitello, Jie Cheng, Nilesh Mathuria
Journal: Journal of the American College of Cardiology (2017)
Busulfan and Cyclophosphamide for Hemopoietic Stem Cell Transplantation from Related and Unrelated Donors in Patients with Myelodysplastic Syndrome
Authors: Jimin Shi, He Huang, Zhen Cai, Yi Luo, Weiyan Zheng, Jingsong He, Wanzhuo Xie, Li Li, Xiujin Ye, Jie Zhang, Maofang Lin
Journal: Blood (2008)
VITAMIN K ANTAGONIST OR DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION: THE IMPORTANCE OF TIME IN THERAPEUTIC RANGE
Authors: Naja Emborg Vinding, Anders Nissen Bonde, Rasmus Rørth, Morten Lamberts, Jonas Bjerring Olesen, Gunnar Gislason, Christian Torp-Pedersen, Lars Køber, Emil Loldrup Fosbøl
Journal: Journal of the American College of Cardiology (2017)
Deletion of the 17p Chromosomal Region Is Associated with a Very Poor Outcome in Multiple Myeloma Independently of the Type of Treatment.
Authors: Hervé Avet-Loiseau, Xavier Leleu, Murielle Roussel, Claire Mathiot, Denis Caillot, Cyrille Hulin, Gerald Marit, Thierry Facon, Michel Attal, Jean-Luc Harousseau, Stéphane Minvielle, Loic Campion, Philippe Moreau
Journal: Blood (2009)
Esophageal cancer incidence gender disparity.
Authors: Luckson Noe Mathieu, Craig Hooker, Norma Kanarek, Charles M. Rudin, Malcolm Brock
Journal: Journal of Clinical Oncology (2012)

1573 Background: Over the past 30 years, esophageal cancer incidence has been increasing more rapidly than any other solid neoplasm in the Western world. Globally, there is a large male predominance in both esophageal squamous and adenocarcinoma. The reasons for this gender difference and the possible role of estrogen are unclear. The objective of this study is to determine if estrogen exposure is consistent with the male predominance observed in esophageal cancer incidence. Methods: A database assessment of esophageal cancer incidence rates (age-adjusted) from 1975 to 2008 was conducted in the National SEER 9 Database and the Maryland Cancer Registry. Rates by gender and age were calculated. Gender-specific incidence rate ratios were compared across age groups. Annual percentage change (APC) was compared for each gender-age group. Results: In both national and state, male and female, adeno and squamous cell histologies, incidence rates increase with patient age. SEER data trends revealed the 50-64 aged female cohort as the only gender-age cohort APC decreasing between 1975-2008. Furthermore, a significant increase in incidence for females is observed in the 65+ age groups; whereas among males, the rates are rising in all age groups. Conclusions: Using age as a proxy for estrogen exposure, our findings suggest a hormonal component in the declining male: female esophageal cancer incidence rate ratios with increasing age and confirm gender differences in incidence long observed in esophageal cancer. Histological features may be predictive of a lower rate ratio. (Bodelon et al. 2011) Estrogen exposure may play a protective role in esophageal cancer which dissipates with time after age 60-69. Our data suggest possible future roles of estrogen as a chemopreventive agent in esophageal cancer (Barone et al. 2011). [Table: see text] [Table: see text]
Non conventional suboptimal doses of gemcitabine (G) at fixed dose rate (FDR) infusion, combined with cisplatin (C), in patients with advanced non-small cell lung cancer (NSCLC)
Authors: O. Caffo, A. Santo, S. Binato, M. Zucchetti, A. Lucenti, M. Centonze, M. Giovannini, M. D'Incalci, G. Cartei, E. Galligioni
Journal: Journal of Clinical Oncology (2004)

7333 Background: C combined with G, at a dose ≥ 1000 mg/sqm., is widely used for advanced NSCLC. It appears that G administered at FDR of 10 mg/sqm/min could enhance its anticancer activity. In the absence of dose-finding and pharmacokinetic (PK) studies of FDR G plus C in NSCLC, we have planned a clinical and PK study to investigate the optimal dose of FDR G. Methods: The treatment consisted of G administered at a fixed dose rate of 10 mg/smq/min on days 1,8 and C (75 mg/sqm) on day 8. Cycles were repeated every 21 days for a maximum of 6 cycles. G was escalated from 600 up to 1200 mg/sqm, with a 100 mg/sqm dose escalation in absence of dose-limiting toxicity; for each cohort we enrolled at least 3 pts. PK samplings were obtained on days 1 & 8 of the first treatment course, in 3 pts per each cohort. Results: A consecutive series of 29 pts (median age 58 y, range 37–71 y) entered this study. Overall, 16 pts received a G dose < 1000 mg/smq and 13 ≥ 1000 mg/sqm. PK data showed that after stratifying by dose level, the target plasma concentration of 10μM was achieved in 8 out of the 12 evaluable pts (70%) treated with 600–900 mg/sqm, but only in 4 out of the 9 evaluable pts (44,4%) treated with 1000–1200 mg/sqm. Toxicity was manageable with 12/29 pts experiencing a grade 3–4 hematological toxicity at all dose levels. Objective responses were observed at all G dose levels: ORR was 56.5% and 46.1% among pts receiving < 1000 mg/sqm and ≥ 1000 mg/sqm respectively (see table). Conclusions: The present data may suggest that unconventional lower doses of G given at FDR could be as effective as conventional doses of G combined with C, in NSCLC. In this prospective we are completing the analysis of PK data, assessing also the correlation with intracellular accumulation of the active metabolite (dFdCTP) of G, in order to verify our data and correlate with the clinical results. No significant financial relationships to disclose.
Coronary Endothelial Dysfunction and the Index of Microcirculatory Resistance as a Marker of Subsequent Development of Cardiac Allograft Vasculopathy
Authors: Jang Hoon Lee, Kozo Okada, Kiran Khush, Yuhei Kobayashi, Seema Sinha, Helen Luikart, Hannah Valantine, Alan C. Yeung, Yasuhiro Honda, William F. Fearon
Journal: Circulation (2017)
The Effects of Pay-for-Performance Programs on Health, Health Care Use, and Processes of Care
Authors: Aaron Mendelson, Karli K. Kondo, Cheryl L. Damberg, Allison Low, Makalapua Motu'apuaka, Michele Freeman, Maya O'Neil, Rose Relevo, Devan Kansagara
Journal: Annals of Internal Medicine (2017)

The effectiveness of pay-for-performance programs, which provide financial rewards or penalties to providers or institutions according to performance on measures of quality, is unclear. This review...
INFLUENCE OF BIOMARKERS OF INFLAMMATION, MYOCARDIAL FIBROSIS, CATECHOLAMINES ON THE SURVIVAL OF CONGESTIVE HEART FAILURE PATIENTS UNDERGOING CARDIAC RESYNCHRONIZATION THERAPY
Authors: Vadim A. Kuznetsov, Tatiana Enina, Olga Nochrina, Tatiana Petelina, Anna Soldatova, Dmitriy Krinochkin, Alexandr Rychkov
Journal: Journal of the American College of Cardiology (2017)
Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801
Authors: T. E. Stinchcombe, L. Hodgson, J. E. Herndon, M. J. Kelley, M. Cicchetti, N. Ramnath, H. B. Niell, J. N. Atkins, M. R. Green, E. E. Vokes
Journal: Journal of Clinical Oncology (2009)

7535 Background: CALGB 39801 was designed to test whether treatment with induction chemotherapy and concurrent chemoradiotherapy (arm B) would improve OS in comparison to identical chemoradiotherapy alone (arm A), and demonstrated no significant benefit in OS for induction therapy. The objective of this analysis was to identify factors predictive of OS, and to use relevant factors to dichotomize pts into prognostic groups. Methods: Between July 1998 and May 2002, 331 pts were studied and included in a Cox proportional hazard regression analysis investigating previously identified prognostic factors: age (&lt; 70 vs. ≥ 70 years), gender, race/ethnicity, hemoglobin (hgb) (&lt; 13 vs. ≥13), performance status (PS) (0 vs.1), pretreatment weight loss (wt loss) (&lt;5% vs. ≥ 5%), and treatment arm. Results: Cox regression analysis identified weight loss ≥ 5%, age ≥ 70, PS of 1, and hgb &lt; 13 as predictive of worse survival (p&lt;0.05), but not treatment arm (p=0.55). The median survival for pts with 0 (n=66), 1 (n=100), 2 (n=100), or ≥ 3 (n=65) risk factors were 24, 18, 10, and 8 months, respectively (p=0.0001). The pts were dichotomized into “poor prognosis” (PP) defined as ≥2 factors (n=165) and “good prognosis” (GP) defined as ≤ 1 factors (n=166). The hazard ratio (HR) for overall survival for the PP in comparison GP was 1.88 (95% CI, 1.49 to 2.37; p-value &lt; 0.0001); the median survival times (MST) observed were 9 and 18 months, respectively (p&lt;0.0001). The reasons for discontinuing treatment, and the rates of hematologic and non-hematologic adverse events were similar between the two groups. In the PP group the OS was similar between arms A (n=82) and B (n=83) (HR=0.97, 95% CI, 0.70 to 1.4; p=0.34); MST of 8.7 and 9.5 months, respectively. In the GP the OS was similar between arms A (n=79) and B (n=87) (HR=0.86, 95% CI, 0.63 to 1.1; p=0.87); MST of 19.3 and 17.6 months, respectively. Conclusions: Factors predictive of OS can be used to dichotomize pts into prognostic groups. Induction chemotherapy was not beneficial in either prognostic group. No significant financial relationships to disclose.
Evaluation of the Risk of Relapse and Survival Using a Conditional Survival Approach in 815 Multiple Myeloma Patients
Authors: Maximilian Schinke, Inga Promny, Gabriele Ihorst, Johannes M. Waldschmidt, Roland H. Mertelsmann, Justus Duyster, Ralph M. Waesch, Martin Schumacher, Monika Engelhardt
Journal: Blood (2016)
CAN NON-PROCEDURAL PATIENT CHARACTERISTICS PREDICT IN-HOSPITAL COMPLICATIONS FOLLOWING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION? IMPLICATIONS FOR SAME-DAY DISCHARGE
Authors: Gaurav Patel, Anvit Rai, Maitri Pancholy, Sukrut Nanavaty, Mark Sandhaus, Aman Patel, Tejas Patel, Hemant Tiwari, John Coppola, Tak Kwan, Samir Pancholy
Journal: Journal of the American College of Cardiology (2017)
Multicenter phase II trial of gemcitabine plus liposomal doxorubicin in chemotherapeutically pretreated patients with advanced breast cancer (ABC
Authors: K. Haider, G. Kornek, W. Kwasny, D. Depisch, T. Payrits, W. Scheithauer, F. Lang
Journal: Journal of Clinical Oncology (2004)

696 Background: To evaluate the safety and efficacy of gemcitabine in combination with lioposomal doxorubicin in pretreated patients with ABC. Methods: Thirty-four patients (pts) with ABC were entered in this multicenter phase II trial in order to investigate the efficacy and tolerance of a combination regimen consisting of gemcitabine (800 mg/m2, days 1 + 8) and liposomal doxorubicin (24 mg/m2 day 1) ± granulocyte colony-stimulating factor (GCSF; 5mcg/kg/d x 5 s.c.), depending on ANCs on the days of scheduled drug administration. Treatment courses were repeated every 3 weeks. Thirty-one pts (91%) are presently evaluable for response and all pts for toxicity assessment. Seven pts were pre- and 27 pts post-menopausal. Their median age was 64 (37–80) years, and the median WHO performance status 1(0–2). Predominant tumor sites were visceral in 26 pts, bone in 6 pts, and soft-tissue in 2 pts, respectively. Twenty-six patients (76%) had 2 or multiple tumor sites. Twenty-seven pts received this regimen as 2nd line therapy, 5 pts as 3rd line and 2 pts as 4th line therapy. Results: After a median of 6 (1–6) courses, an overall response rate of 29% (9/31) was observed; 14 pts had disease stabilization (45%), and 8 (26%) progressed. The median progression-free survival is 7.0 months (1.5 to 20), and median overall survival (>11 months) has not been reached yet with 22 pts (65%) still alive. WHO grade 3 or 4 neutropenia occurred in 10 (29%) and 1 (3%) pts; grade 3 or 4 thrombocytopenia was seen in 2 (6%) and 1 (3%) pts. Nonhematologic side effects were generally mild to moderate (except 1 pt who had grade 3 nausea + stomatitis) and included nausea/vomiting (47%), stomatitis (47%), fatigue (45%), hand & foot-syndrome (35%), peripheral neuropathy (12%), constipation (12%), increased transaminases (12%), diarrhea (9%), anaphylaxis (12%), conjunctivitis (12%), and infection (3%). Conclusions: We conclude that gemcitabine and liposomal doxorubicin ± G-CSF is an effective and fairly well tolerated regimen for chemotherapeutically pretreated pts with ABC. No significant financial relationships to disclose.